Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 8,974,834 shares, a drop of 46.2% from the October 15th total of 16,679,713 shares. Based on an average trading volume of 3,629,551 shares, the days-to-cover ratio is presently 2.5 days. Currently, 8.1% of the company’s shares are sold short.
Perspective Therapeutics Trading Down 0.5%
NYSEAMERICAN CATX traded down $0.01 on Monday, reaching $0.94. The stock had a trading volume of 2,013,385 shares, compared to its average volume of 2,411,416. The firm has a fifty day moving average of $2.11 and a two-hundred day moving average of $3.44. Perspective Therapeutics has a 1-year low of $0.78 and a 1-year high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Research analysts anticipate that Perspective Therapeutics will post -1.01 earnings per share for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Report on Perspective Therapeutics
Insiders Place Their Bets
In related news, CEO Johan Spoor purchased 47,000 shares of the firm’s stock in a transaction on Wednesday, November 11th. The shares were bought at an average price of $0.81 per share, for a total transaction of $38,070.00. Following the acquisition, the chief executive officer directly owned 106,383 shares in the company, valued at $86,170.23. This trade represents a 79.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Markus Puhlmann bought 35,000 shares of the firm’s stock in a transaction dated Thursday, November 12th. The shares were purchased at an average price of $0.84 per share, with a total value of $29,400.00. Following the acquisition, the insider directly owned 178,542 shares in the company, valued at approximately $149,975.28. This trade represents a 24.38% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 151,648 shares of company stock worth $128,314. Corporate insiders own 2.99% of the company’s stock.
Institutional Investors Weigh In On Perspective Therapeutics
A number of large investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in shares of Perspective Therapeutics in the third quarter valued at $4,075,000. Empowered Funds LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $338,000. Nantahala Capital Management LLC raised its position in Perspective Therapeutics by 7.2% in the third quarter. Nantahala Capital Management LLC now owns 2,492,642 shares of the company’s stock worth $6,855,000 after acquiring an additional 167,192 shares during the period. Voya Investment Management LLC grew its position in shares of Perspective Therapeutics by 34.4% during the 3rd quarter. Voya Investment Management LLC now owns 453,650 shares of the company’s stock valued at $1,248,000 after acquiring an additional 116,149 shares during the period. Finally, Russell Investments Group Ltd. grew its position in shares of Perspective Therapeutics by 53.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after acquiring an additional 21,150 shares during the period. 54.66% of the stock is currently owned by institutional investors and hedge funds.
Perspective Therapeutics Company Profile
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Recommended Stories
- Five stocks we like better than Perspective Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
